Anticoagulant profile of supplementary-dose enoxaparin in patients undergoing prolonged percutaneous coronary intervention

Abstract Background Enoxaparin 0.75 mg/kg, with either a staged-dose regimen (0.5+0.25 mg/dl) or single-dose (0.75 achieves target anticoagulation for 90 min in patients undergoing percutaneous coronary intervention (PCI). In prolonged procedures (>90 min), supplementary-dose enoxaparin (0.375 mg/kg) needs to be given at maintain additional min. However, the actual anticoagulant profile of this remains unknown because it is recommended only based on pharmacokinetic simulations. Purpose This study directly assessed troponin-negative elective trans-radial PCI who received total dose mg/kg during first their procedures. Methods 33 procedures, 15 0.5 beginning angiography and 0.25 before (Staged-dose regimen); while, 18 without (Single-dose regimen). A was administered after given, every thereafter until end PCI. Anti-Xa levels were 0 (immediately before), 10 each supplementary (S_0min, S_10min, S_90min, respectively). Target defined as anti-Xa level 0.5–1.8 IU/ml. Results one (n=28), S1_0min: 0.87±0.19 IU/ml, S1_10min: 1.44±0.21 S1_90min: 1.10±0.21 two doses (n=5), 0.86±0.07 1.27±0.27 1.03±0.23 well S2_0min: S2_10min: 1.56±0.28 S2_90min: 1.28±0.18 respectively. No patient more than enoxaparin. All within range except receiving (S1_10min: 1.96 IU/ml 1.81 respectively) another (S2_10min: 1.87 IU/ml). Conclusions mg/kg), which thereafter, maintained time given. Funding Acknowledgement Type funding sources: Public hospital(s). Main source(s): Peking Union Medical College Hospital (PUMCH) Science Fund Junior Faculty